These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 25345874

  • 1. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M.
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [Abstract] [Full Text] [Related]

  • 4. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.
    Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046
    [Abstract] [Full Text] [Related]

  • 5. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD, Despotovic J, Roy J, Grainger J, Cooper N, Beam D, Raj A, Maschan A, Kim J, Eisen M.
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [Abstract] [Full Text] [Related]

  • 6. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
    Lancet; 2016 Jul 02; 388(10039):45-54. PubMed ID: 27103127
    [Abstract] [Full Text] [Related]

  • 7. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM.
    Drugs; 2012 Feb 12; 72(3):415-35. PubMed ID: 22316355
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE.
    Ter Arkh; 2018 Aug 17; 90(7):70-76. PubMed ID: 30701925
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
    Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.
    Blood; 2011 Jul 07; 118(1):28-36. PubMed ID: 21502541
    [Abstract] [Full Text] [Related]

  • 13. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M.
    Br J Haematol; 2016 Jan 07; 172(2):262-73. PubMed ID: 26537623
    [Abstract] [Full Text] [Related]

  • 14. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
    Grainger J, Bussel J, Tarantino M, Cooper N, Beam D, Despotovic J, Maschan A, Wang K, Eisen M, Bowers C.
    Blood Adv; 2023 Feb 14; 7(3):396-405. PubMed ID: 35413092
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M.
    J Clin Pharm Ther; 2014 Aug 14; 39(4):376-82. PubMed ID: 24702274
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Červinek L, Terrell DR, Wang X, Franklin J.
    Ann Hematol; 2016 Jun 14; 95(7):1077-87. PubMed ID: 27130310
    [Abstract] [Full Text] [Related]

  • 19. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
    Doobaree IU, Newland A, McDonald V, Nandigam R, Mensah L, Leroy S, Seesaghur A, Patel H, Wetten S, Provan D.
    Eur J Haematol; 2019 May 14; 102(5):416-423. PubMed ID: 30758874
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.